1	Al	al	SP+DA	-	-	0-2	91(1)_ANS_clinical_caseMIR	SENT1	-	-
2	tratar	tratar	VMN0000	-	-	3-9	91(1)_ANS_clinical_caseMIR	SENT1	-	-
3	se	se	PP3CN000	-	-	9-11	91(1)_ANS_clinical_caseMIR	SENT1	-	-
4	de	de	SPS00	C0332285	atributo	12-14	91(1)_ANS_clinical_caseMIR	SENT1	-	-
5	un	un		C0205447_1	calificador_1	15-17	91(1)_ANS_clinical_caseMIR	SENT1	-	-
6	efecto	efecto	NCMS000	C1704419#C1280500#C1280519	calificador	18-24	91(1)_ANS_clinical_caseMIR	SENT1	-	-
7	sobre	sobre	SPS00	C1720294#C0205136	calificador	25-30	91(1)_ANS_clinical_caseMIR	SENT1	-	-
8	las	el	DA0FP0	-	-	31-34	91(1)_ANS_clinical_caseMIR	SENT1	-	-
9	mitocondrias	mitocondria	NCFP000	C0026237	estructura_celular	35-47	91(1)_ANS_clinical_caseMIR	SENT1	-	-
10	.	.	Fp	-	-	47-48	91(1)_ANS_clinical_caseMIR	SENT1	-	-

1	La	el	DA0FS0	-	-	49-51	91(1)_ANS_clinical_caseMIR	SENT2	-	-
2	enfermedad	enfermedad	NCFS000	C0012634#C0039082	trastorno	52-62	91(1)_ANS_clinical_caseMIR	SENT2	-	-
3	únicamente	únicamente	RG	-	-	63-73	91(1)_ANS_clinical_caseMIR	SENT2	-	-
4	se	se	P00CN000	-	-	74-76	91(1)_ANS_clinical_caseMIR	SENT2	-	-
5	transmitirá	transmitir	VMIF3S0	-	-	77-88	91(1)_ANS_clinical_caseMIR	SENT2	-	-
6	vía	vía	NCFS000	C0449444	atributo	89-92	91(1)_ANS_clinical_caseMIR	SENT2	-	-
7	materna	materno	AQ0FS0	-	-	93-100	91(1)_ANS_clinical_caseMIR	SENT2	-	-
8	(	(	Fpa	-	-	101-102	91(1)_ANS_clinical_caseMIR	SENT2	-	-
9	herencia	herencia	NCFS000	C0728826	atributo	102-110	91(1)_ANS_clinical_caseMIR	SENT2	-	-
10	materna	materno	AQ0FS0	-	-	111-118	91(1)_ANS_clinical_caseMIR	SENT2	-	-
11	)	)	Fpt	-	-	118-119	91(1)_ANS_clinical_caseMIR	SENT2	-	-
12	,	,	Fc	-	-	119-120	91(1)_ANS_clinical_caseMIR	SENT2	-	-
13	por	por	SPS00	C0678226	atributo	121-124	91(1)_ANS_clinical_caseMIR	SENT2	-	-
14	lo	el	DA0NS0	-	-	125-127	91(1)_ANS_clinical_caseMIR	SENT2	-	-
15	que	que	PR0CN000	-	-	128-131	91(1)_ANS_clinical_caseMIR	SENT2	-	-
16	no	no	RN	C1298908	calificador	132-134	91(1)_ANS_clinical_caseMIR	SENT2	-	-
17	existe	existir	VMIP3S0	-	-	135-141	91(1)_ANS_clinical_caseMIR	SENT2	-	-
18	riesgo	riesgo	NCMS000	-	-	142-148	91(1)_ANS_clinical_caseMIR	SENT2	-	-
19	.	.	Fp	-	-	148-149	91(1)_ANS_clinical_caseMIR	SENT2	-	-

